PRI officially trademarked the Projections Research logo. We are very excited to have our exclusive logo!

Dr. Diane Mould was awarded the Jack L Beal Alumni Award by the Ohio State University College of Pharmacy. The award will be presented May 7 in Columbus. To receive the award the recipients must have a professional degree (B.S., M.S., Pharm.D.) from the OSU College of Pharmacy, have made distinguished contributions in the fields of public health and public service, have performed outstanding activities in the interest of the College and its students, and have an outstanding record in the profession of pharmacy. Congratulations Diane!

PRI team member Bill Frame has a website www.thtxinfo.com which contains a lot of great Nonmem tutorial information along with some other interesting items.

Dr. Diane Mould was invited to speak at the Korean Society for Clinical Pharmacology and Therapeutics and American Society for Clinical Pharmacology and Therapeutics joint conference held in Seoul, Korea. She lectured on disease progression modeling to over 100 attendants.

Dr. Diane Mould was invited by the Chinese government and the National Institute of Health, to give a course lecture on clinical pharmacology in Bejing. The lecture covered such topics as population pharmacokinetics and disease progression modeling. There were 70 people in attendance for the hour long lecture. Dr. Mould is pictured with Dr Juan Lertora, head of the department of clinical pharmacology at the NIH.

Dr. Mould has been elected a fellow of the American College of Clinical Pharmacology. Congratulations Dr. Mould!

A preponderance of zeros may occur with several types of data. With interval data one may have a large proportion of actual zero values. For example, if income is the response being modeled, there could be many subjects with no income. With ordinal data one may be faced with the problem that most subjects have all zero values. If adverse event data is being modeled and 0 reflects no adverse event, then one might have a large fraction of subjects with all zero values. PRI in conjunction with several pharmaceutical companies has been exploring ways to model such responses. These include altered zero, added zero, mover-stayer, and sojourn models to name a few.

Big development for Dr. Mould, she has been invited to join the editorial review board for Clinical Pharmacology & Therapeutics. It is an honor she has proudly accepted. Congratulations Dr. Mould!

Dear Dr. Mould,

With the 2007 transition both in editorial leadership and publisher (Nature) complete, the principle journal for the discipline of pharmacology, Clinical Pharmacology & Therapeutics, is now moving forward with other initiatives to improve the journal, which includes building the Editorial Board.

Comprised of ~60 subject matter experts across the fields of pharmacology and clinical pharmacology, the Editorial Board serves as the backbone for the high quality content of the journal. We are populating the Editorial Board with experts from academia, government, and pharma, while maintaining diversity to reflect the demographics in authors and readership.

We believe your participation on the Editorial Board is important to its future success and invite you to join this outstanding team of experts. Your responsibilities would include reviewing ~10 manuscripts each year, providing topical and authorial suggestions for contributions to the journal, contributing articles on occasion to the journal, and participating in the Editorial Board Meeting at the annual ASCPT meeting.

I hope you will be willing to share your expertise and serve the Journal, the Society, and the discipline by joining the Journal s Editorial Board. I would be happy to discuss this invitation in more detail and ask that you contact me if you have any questions or concerns.

Warmest regards,
Elise Laffman-Johnson
Managing Editor
Clinical Pharmacology & Therapeutics

PRI is currently working with a major university to host a 3 week introductory NONMEM course. We will post more information as soon as we have specific details.

PRI has been working on pharmacodynamic models that can handle 0 data values effectively. In some cases, the pharmacodynamic effects of a drug can remove or decrease a pharmacodynamic response to a 0 value, which can result in numerical instability. PRI is now investigating methods of handling these 0 values. We will provide more on this topic in the next installment!